All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2024-12-02T10:22:30.000Z

ASH 2024 abstracts: What’s hot in GvHD?

By Ella Dixon
Featured
Ali Bazarbachi
Amin Alousi
Arnon Nagler
Attilio Olivieri
Bipin Savani
Florent Malard
Frederic Baron
Grzegorz Basak
Hildegard Greinix
Mohamad Mohty
Mutlu Arat
Robert Zeiser
Steven Pavletic
Takanori Teshima
Yi-Bin Chen
Zinaida Peric
Dec 2, 2024
Share:

Bookmark this article

To help navigate the exciting content presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub Steering Committee members provided their recommendations for the top presented abstracts in GvHD.

Saturday, December 7, 2024

Abstract #

Title

Speaker

Time

97

JAK/Rock Inhibitor Rovadicitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease: Updated Results of Multicenter, Phase 1b/2a Trial

Yanmin Zhao

09:30

98

Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the Agave-201 Study

Hannah Choe

09:45

99

A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment

Depei Wu

10:00

100

Safety and Efficacy of the Glucagon-like Peptide 2 (GLP-2) Analog Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease (aGvHD) in Combination with Best Available Therapy: Results from a Multicenter, Randomized, Single-Blind, Proof-of-Concept, Phase 2 Stargaze Trial

Robert Zeiser

10:15

259

Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical Gvhd Models

Jenny Paredes

14:00

384

Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

Yu Akahoshi

17:15

Monday, December 9, 2024

Abstract #

Title

Speaker

Time

1039

Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Sameem Abedin

16:30

1042

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Sameem Abedin

17:15

1043

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Haris Ali

17:30

1044

A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation

Hengwei Wu

17:45

 

ASH 2024 abstracts

To download this document, click below.

Download here

More about...
Acute graft-versus-host diseaseAGAVE-201ASH 2024Chronic graft-versus-host diseaseGraft-versus-host disease

Related articles

Add bookmark

ASH 2023 abstracts: What’s hot in GvHD?

To help navigate the exciting content presented at the 65th ASH Annual Meeting, the GvHD Hub Steering Committee members provided their recommendations for the top presented abstracts in GvHD.

Dec 1, 2023
Add bookmark

ASH 2023 abstracts: What’s hot in GvHD?

To help navigate the exciting content presented at the 65th ASH Annual Meeting, the GvHD Hub Steering Committee members provided their recommendations for the...

Dec 1, 2023
Add bookmark

ASH 2022 abstracts: What’s hot in GvHD?

To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub Steering Committee members provided their recommendations for the top...

Dec 1, 2022
Add bookmark

ASH 2022 abstracts: What’s hot in GvHD?

To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub Steering Committee...

Dec 1, 2022

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox